Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder
Main Author: | Andreas Bohle |
---|---|
Format: | Article |
Language: | English |
Published: |
Sociedade Brasileira de Urologia
2010-08-01
|
Series: | International Brazilian Journal of Urology |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000400024 |
Similar Items
-
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993)
by: Andreas Bohle
Published: (2011-04-01) -
Disseminated Granulomatous Disease from Intravesical Instillation of Bacillus Calmette-Guerin
by: Sayed Ab. Reshad Ghafouri, et al.
Published: (2018-01-01) -
Reiter's syndrome postintravesical Bacillus Calmette–Guérin instillations
by: Keng Lim Ng, et al.
Published: (2017-03-01) -
Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
by: Bedeir Ali-El-Dein, et al.
Published: (2013-01-01) -
Penile lesion with inguinal adenopathy after intravesical Bacillus Calmette-Guerin instillation therapy
by: Guven Aslan, et al.
Published: (2013-01-01)